Pipeline / 02 · Infectious Disease

Pandemic Preparedness Platform

Antiviral therapeutic technologies and rapid-response treatment systems architected for the next unknown pathogen.

RESPONSE LATENCY · REACTIVE vs PLATFORM The first wave crests while conventional development starts from zero. MONTH 0 MONTH 3 MONTH 6 MONTH 12 MONTH 18+ REACTIVE Outbreak identified Sequence released Development begins Clinical trials Emergency approval PLATFORM Outbreak identified Re-target platform Antibody ready Trials begin Deployment at scale
Reactive vs platform-based response. Conventional development starts from zero after the outbreak is named. A pre-built platform re-targets in weeks, compressing the first-wave window where containment is still possible.
Premise

The problem we are solving.

The next pandemic will not arrive at our convenience. By the time an outbreak is named, the first patients are already infected — and by the time a bespoke therapy is developed, the first wave has already crested. Preparedness means having a platform ready to re-target within weeks, not a program ready to start from zero.

COVID-19 demonstrated both the possible and the unacceptable. mRNA platforms moved at unprecedented speed; equitable global distribution did not. Future preparedness must address both — the molecular speed of response, and the logistical reach of deployment.

Approach

How we tackle it.

The Pandemic Preparedness platform is the integration layer across MACRO HRD's other programs — not a separate research project. It draws on three existing capabilities: the functional peptide platform (broad-spectrum antiviral activity, demonstrated against multiple enveloped viruses including Zika, Dengue, and HIV); the multi-specific antibody platform (rapid re-targeting against a new pathogen surface protein); and ambient cell logistics (deployment to affected regions without cold-chain dependency).

GEDM-3DQ provides the decision-intelligence backbone — modeling outbreak trajectories, optimizing intervention sequencing across patient cohorts, and coordinating cross-site response. The principle is platform readiness: when a new pathogen emerges, the response is to re-parameterize existing systems, not to build new ones from scratch.

READINESS ARCHITECTURE Four platforms, already running. 01 AH-D Peptide Broad-spectrum Membrane-disruption activity across enveloped viruses. Re-targetable without redesign. 02 Antibody Re-targeting Weeks, not years Trispecific antibody framework already modular; new binding arms swappable against emerging pathogens. 03 Ambient Logistics Global reach PG-coated formulations ship at ambient temperature — no cold chain required for last-mile delivery. 04 GEDM-3DQ Decision intelligence Outbreak trajectory modeling, intervention sequencing across cohorts, cross-site coordination at scale.
Four MACRO HRD platforms combine into a standing readiness architecture — AH-D broad-spectrum peptide, modular trispecific antibody framework, ambient-temperature logistics, and GEDM-3DQ decision intelligence.
Capabilities

What makes this real.

01
Broad-spectrum AH-D peptide
Lipid envelope disruption mechanism active against enveloped viruses generally. New pathogen response begins with screening, not synthesis.
02
Rapid antibody re-targeting
Tri-specific antibody platform with modular binding domains — re-targeting timeline measured in weeks rather than years.
03
Ambient deployment chain
Therapies formulated for room-temperature distribution leverage the sporulation-strategy logistics platform, eliminating cold-chain bottlenecks at the point of use.
04
Outbreak-modeling decision layer
GEDM-3DQ adapts its trajectory reasoning to outbreak dynamics — optimizing intervention sequencing across cohorts and sites in real time.
Where It Connects

Part of an integrated platform.

01 · Platforms
Functional Peptide Platform
A library of 20,000+ engineered peptides for membrane penetration, targeted delivery, and biological modulation.
01 · Platforms
Multi-Specific Antibody Platform
Tri-specific antibody systems for precision targeting, immune recruitment, and viral escape prevention.
04 · Infrastructure
Ambient Cell Logistics
Room-temperature cell logistics — a bioinspired sporulation strategy that ends cold-chain dependency for cellular therapies.
01 · Platforms
GEDM-3DQ Decision Engine
Gradient Equilibrium Decision Modeling in 3-Dimensional Quadrant — the AI spine of every MACRO HRD program.
⸻ Continue the platform

“The next pandemic will not negotiate. Our preparedness must already be built.”

See all ventures → Engage with MACRO HRD